文献速递呼吸道感染肺栓塞与肺血管病呼吸危重症与机械通气

高剂量预防性抗凝对重症COVID-19肺炎患者的影响

Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia.
PubMed 文献 · Chest · 2021-01-16

这项法国多中心观察性研究纳入538例连续收治于8个ICU的COVID-19重症患者,随访至第14天,采用时间依赖暴露模型评估高剂量预防性抗凝的效果。结果显示血栓并发症发生率为22.7%(95%CI 19.2%-26.3%),高剂量预防性抗凝与血栓并发症风险降低相关(HR 0.81;95%CI 0.66-0.99),且未增加出血风险(HR 1.11;95%CI 0.70-1.75)。

要点

  • 重症COVID-19患者血栓并发症发生率为22.7%(95%CI 19.2%-26.3%),其中肺栓塞占52%。
  • 高剂量预防性抗凝与血栓并发症风险降低相关(HR 0.81;95%CI 0.66-0.99)。
  • 高剂量预防性抗凝未增加出血风险(HR 1.11;95%CI 0.70-1.75)。

核心结论

  • 高剂量预防性抗凝与重症COVID-19患者血栓并发症减少相关,且不增加出血风险。
  • 作者认为需要随机对照试验比较更高剂量抗凝与标准预防以确认这些结果。

研究设计与样本

  • 法国8个ICU的观察性研究,连续纳入因COVID-19收治的全部患者。
  • 共纳入538例患者,收集ICU入住至第14天的临床与实验室数据,包括抗凝状态及血栓和出血事件。
  • 采用标准化分类方案定义高剂量预防性抗凝(中间剂量或等效治疗剂量),并用逆概率治疗加权的时间依赖暴露模型评估其效应。

主要发现

  • 538例患者中104例共发生122次血栓并发症,发生率为22.7%(95%CI 19.2%-26.3%)。
  • 肺栓塞占记录血栓并发症的52%。
  • 高剂量预防性抗凝与血栓并发症风险显著降低相关(HR 0.81;95%CI 0.66-0.99)。
  • 高剂量预防性抗凝未增加出血风险(HR 1.11;95%CI 0.70-1.75)。

临床怎么用

  • 对重症COVID-19肺炎患者,可考虑高剂量预防性抗凝以降低血栓并发症风险。
  • 临床决策时需结合出血风险评估,该策略在本研究中未增加出血风险。

局限性

  • 为观察性研究,高剂量预防性抗凝的获益需随机对照试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Because of the high risk of thrombotic complications (TCs) during SARS-CoV-2 infection, several scientific societies have proposed to increase the dose of preventive anticoagulation, although arguments in favor of this strategy are inconsistent. RESEARCH QUESTION: What is the incidence of TC in critically ill patients with COVID-19 and what is the relationship between the dose of anticoagulant therapy and the incidence of TC? STUDY DESIGN AND METHODS: All consecutive patients referred to eight French ICUs for COVID-19 were included in this observational study. Clinical and laboratory data were collected from ICU admission to day 14, including anticoagulation status and thrombotic and hemorrhagic events. The effect of high-dose prophylactic anticoagulation (either at intermediate or equivalent to therapeutic dose), defined using a standardized protocol of classification, was assessed using a time-varying exposure model using inverse probability of treatment weight. RESULTS: Of 538 patients included, 104 patients experienced a total of 122 TCs with an incidence of 22.7% (95% CI, 19.2%-26.3%). Pulmonary embolism accounted for 52% of the recorded TCs. High-dose prophylactic anticoagulation was associated with a significant reduced risk of TC (hazard ratio, 0.81; 95% CI, 0.66-0.99) without increasing the risk of bleeding (HR, 1.11; 95% CI, 0.70-1.75). INTERPRETATION: High-dose prophylactic anticoagulation is associated with a reduction in thrombotic complications in critically ill patients with COVID-19 without an increased risk of hemorrhage. Randomized controlled trials comparing prophylaxis with higher doses of anticoagulants are needed to confirm these results. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04405869; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Tacquard C, Mansour A, Godon A, et al. Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia. Chest. 2021. PMID: 33465342. doi:10.1016/j.chest.2021.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。